Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m…
Metabolic Disorders
-
-
Echosens and Boehringer expand partnership for MASH diagnosis
Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in metabolic dysfunction-associated steatohepatitis (MASH) diagnosis and care.…
-
MHRA warns women using weight loss jabs must use effective contraception
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has warned that women using weight loss jabs must use effective…
-
FDA rejects Stealth Bio’s Barth syndrome treatment after 16.5-month review
The US Food and Drug Administration (FDA) has rejected Stealth BioTherapeutics’ elamipretide for the treatment of Barth syndrome after a…
-
Wegovy and Zepbound costs capped at $200 in new Evernorth programme
Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal with drugmakers Novo Nordisk and Eli…
-
Skye and Arecor to develop higher formulation of CB1 inhibitor
Skye Bioscience has partnered with Arecor Therapeutics to develop a higher formulation of the former’s obesity candidate nimacimab, a cannabinoid receptor…
-
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies
As competition continues to intensify in the obesity treatment market, Novo Nordisk has struck a collaboration and licencing deal worth…
-
GSK to spend $2bn on Phase III liver disease drug acquisition
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire…
-
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Novo Nordisk has reduced its sales and profits forecasts for 2025 due to lower-than-expected demand in the US for blockbuster…
-
FDA accepts Novo Nordisk’s NDA submission for weight management therapy
The US Food and Drug Administration (FDA) has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg…
